NCT07395687 A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
| NCT ID | NCT07395687 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Novo Nordisk A/S |
| Condition | Overweight |
| Study Type | INTERVENTIONAL |
| Enrollment | 333 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2027-01-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 333 participants in total. It began in 2026-02-02 with a primary completion date of 2027-01-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.
Eligibility Criteria
Inclusion Criteria: 1. Male or female (sex at birth). 2. For Part C: Japanese, Chinese or non-Asian participants (all self-reported): * For Japanese participants: both parents of Japanese descent. * For Chinese participants: both parents of Chinese descent. * For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia). 3. Age at the time of signing the informed consent: 1. For Part A: 18-55 years (both inclusive) 2. For Part B: 18-65 years (both inclusive) 3. For Part C: 18-55 years (both inclusive). 4. BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator): 1. For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive) 2. For Part B: 30.0-50.0 kg/m\^2 (both inclusive) 3. For Part C: 24-34.9 kg/m\^2 (both inclusive) 5. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: 1. Known or suspected hypersensitivity to study intervention(s) or related products. 2. Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening. 3. Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
Contact & Investigator
Clinical Transparency (dept. 2834)
STUDY DIRECTOR
Novo Nordisk A/S
Frequently Asked Questions
Who can join the NCT07395687 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Overweight. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07395687 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07395687 currently recruiting?
Yes, NCT07395687 is actively recruiting participants. Contact the research team at clinicaltrials@novonordisk.com for enrollment information.
Where is the NCT07395687 trial being conducted?
This trial is being conducted at Cypress, United States, Overland Park, United States, Montreal, Canada.
Who is sponsoring the NCT07395687 clinical trial?
NCT07395687 is sponsored by Novo Nordisk A/S. The principal investigator is Clinical Transparency (dept. 2834) at Novo Nordisk A/S. The trial plans to enroll 333 participants.